Sobi Submits Application for Orfadin to EMA

Article

Sobi's application for Orfadin oral suspension has been validated by EMA.

Sobi announced that the company's application for Orfadin oral suspension has been validated by EMA. This new dosage form has been developed to facilitate the accuracy in administration of the desired Orfadin dose to pediatric patients and to increase expediency for the patients and their caregivers.
 
The oral suspension is included in a Paediatric Investigation Plan agreed with EMA in March 2012.

Source: Sobi

Recent Videos
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Leroy Hood, MD, PhD
Behind the Headlines, Episode 10
Related Content